论文部分内容阅读
目的:观察分析诺和锐30联合二甲双胍在2型糖尿病患者中的临床疗效。方法:收治2型糖尿病患者116例,对比患者治疗前后的相关血糖指标。结果:患者在接受治疗后其血糖水平均基本恢复正常。对比患者治疗前后,空腹血糖水平出现显著下降与治疗前对比差异有显著性(P<0.01);餐后2小时的血糖水平,治疗前后对比差异有显著性(P<0.01);糖化血红蛋白治疗前后也差异有显著性(P<0.01)。116例患者在治疗期间均没有出现严重的不良反应,没有出现有严重的低血糖事件。结论:诺和锐30联合二甲双胍用于2型糖尿病治疗能够取得满意的临床结果,并且用药相对较安全。
Objective: To observe and analyze the clinical efficacy of Novo-Rui 30 combined with metformin in type 2 diabetes. Methods: A total of 116 patients with type 2 diabetes mellitus were enrolled in this study. The related blood glucose levels before and after treatment were compared. Results: The blood glucose level of the patients returned to normal after receiving the treatment. The level of fasting blood glucose decreased significantly compared with that before treatment (P <0.01). The level of blood glucose at 2 hours after the meal was significantly lower than that before treatment (P <0.01). Before and after treatment with HbA1c There was also a significant difference (P <0.01). None of the 116 patients experienced any serious adverse reactions during treatment and no severe hypoglycaemia occurred. Conclusions: Novo-Rui 30 combined with metformin can be used to treat type 2 diabetes patients with satisfactory clinical results, and the medication is relatively safe.